'Breakthrough' mRNA cancer drug curbs melanoma in large trial

US drugmakers Merck and Moderna said a personalised cancer treatment had shown success in reducing the recurrence of melanoma tumours in a late-stage trial hailed by experts as a "breakthrough". The news sent shares in Moderna soaring 145 per cent to $154 while Merck's stock was up more than 12 per cent to $152. The drug, called "intismeran autogene,"